FO
CLVS

FT Options’s Clovis Oncology, Inc. CLVS Stock Holding History

FT Options’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$1.56M Sell
84,200
-61,000
-42% -$4.84M 2.36% 9
2017
Q2 		$3.56M Buy
145,200
+131,700
+976% +$8.06M 6.14% 2
2017
Q1 		$89K Buy
+13,500
New +$821K 0.12% 120
2016
Q4 		– Sell
-54,400
Closed -$212K – 406
2016
Q3 		$212K Buy
54,400
+30,000
+123% +$644K 0.17% 104
2016
Q2 		$7K Sell
24,400
-5,200
-18% -$76K 0.01% 297
2016
Q1 		$98K Sell
29,600
-10,100
-25% -$214K 0.1% 125
2015
Q4 		$77K Buy
+39,700
New +$2.56M 0.06% 142

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FT Options's CLVS Position: Q3 2017 in Review

FT Options reduced its Clovis Oncology, Inc. (CLVS) stake by 48% in Q3 2017, selling an estimated $1.56M and leaving 21,787 shares worth $1.79M. The position accounts for 2.71% of the portfolio, ranked #6.

FT Options first reported a position in CLVS in Q4 2015 and has held it in 7 quarters since. The position peaked at $3.89M in Q2 2017. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

  • FT Options held 21,787 shares of Clovis Oncology, Inc. worth $1.79M as of Q3 2017.
  • FT Options sold 19,713 Clovis Oncology, Inc. shares in Q3 2017, an estimated $1.56M.
  • Clovis Oncology, Inc. made up 2.71% of FT Options's portfolio in Q3 2017, its #6 holding.
  • FT Options first reported a position in Clovis Oncology, Inc. in Q4 2015 and has held it in 7 quarters since.
  • FT Options's Clovis Oncology, Inc. position peaked at $3.89M in Q2 2017.
  • 255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.